BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

2259

500288

MOREPENLAB

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

MOREPEN LAB. LTD performance

Today’s low

Today’s high

₹ 59.61 ₹ 62.73
₹ 60.17

52 week low

52 week high

₹ 42.00 ₹ 100.90
₹ 60.17

Open Price

₹ 62.60

Prev. Close

₹ 62.63

Volume (Shares)

6134537.00

Total traded value

₹ 3691.15

Upper Circuit

₹ 75.15

Lower Circuit

₹ 50.10

info

MOREPEN LAB. LTD Share Price Update

As of the latest trading session, MOREPEN LAB. LTD share price is currently at ₹ 60.17, which is down by ₹ -2.46 from its previous closing. Today, the stock has fluctuated between ₹ 59.61 and ₹ 62.73. Over the past year, MOREPEN LAB. LTD has achieved a return of 20.21 %. In the last month alone, the return has been 21.85 %. Read More...

MOREPEN LAB. LTD fundamentals


  • Market cap (Cr)

    3,075.70

  • P/E Ratio (TTM)

    25.45

  • Beta

    1.59

  • Book Value / share

    20.95

  • Return on equity

    13.29%

  • EPS (TTM)

    2.37

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    22.69

info icon alternate text
  • Market cap (Cr)

    3,067.01

  • P/E Ratio (TTM)

    25.45

  • Beta

    1.48

  • Book Value / share

    20.95

  • Return on equity

    13.29%

  • EPS (TTM)

    2.37

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    22.69

info icon alternate text

MOREPEN LAB. LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 403.25
Operating Expense 377.76
Net Profit 22.69
Net Profit Margin (%) 5.62
Earnings Per Share (EPS) 0.41
EBITDA 36.46
Effective Tax Rate (%) 25.31
Particulars SEP 2024 (Values in Cr)
Revenue 383.70
Operating Expense 345.48
Net Profit 31.93
Net Profit Margin (%) 8.32
Earnings Per Share (EPS) 0.60
EBITDA 47.69
Effective Tax Rate (%) 25.50
Particulars JUN 2024 (Values in Cr)
Revenue 385.64
Operating Expense 341.66
Net Profit 35.05
Net Profit Margin (%) 9.08
Earnings Per Share (EPS) 0.69
EBITDA 51.67
Effective Tax Rate (%) 25.50
Particulars MAR 2024 (Values in Cr)
Revenue 392.60
Operating Expense 343.88
Net Profit 39.96
Net Profit Margin (%) 10.17
Earnings Per Share (EPS) 0.78
EBITDA 60.12
Effective Tax Rate (%) 24.18
Particulars DEC 2023 (Values in Cr)
Revenue 394.63
Operating Expense 351.06
Net Profit 35.20
Net Profit Margin (%) 8.91
Earnings Per Share (EPS) 0.69
EBITDA 54.76
Effective Tax Rate (%) 25.45
Particulars MAR 2024 (Values in Cr)
Revenue 1537.59
Operating Expense 1401.18
Net Profit 110.94
Net Profit Margin (%) 7.21
Earnings Per Share (EPS) 2.17
EBITDA 174.39
Effective Tax Rate (%) 25.53
Particulars MAR 2023 (Values in Cr)
Revenue 1338.88
Operating Expense 1281.60
Net Profit 46.24
Net Profit Margin (%) 3.45
Earnings Per Share (EPS) 0.92
EBITDA 83.03
Effective Tax Rate (%) 26.64
Particulars MAR 2022 (Values in Cr)
Revenue 1449.27
Operating Expense 1333.95
Net Profit 101.06
Net Profit Margin (%) 6.97
Earnings Per Share (EPS) 2.25
EBITDA 139.36
Effective Tax Rate (%) 19.49
Particulars MAR 2021 (Values in Cr)
Revenue 1112.42
Operating Expense 1029.95
Net Profit 94.25
Net Profit Margin (%) 8.47
Earnings Per Share (EPS) 2.10
EBITDA 124.15
Effective Tax Rate (%) 0.00
Particulars MAR 2020 (Values in Cr)
Revenue 791.99
Operating Expense 763.93
Net Profit 32.33
Net Profit Margin (%) 4.08
Earnings Per Share (EPS) 0.72
EBITDA 73.88
Effective Tax Rate (%) 13.74
Particulars MAR 2024 (Values in Cr)
Book Value / Share 16.58
ROE % 12.08
ROCE % 16.12
Total Debt to Total Equity 0.03
EBITDA Margin 10.21
Particulars MAR 2023 (Values in Cr)
Book Value / Share 14.73
ROE % 5.81
ROCE % 8.02
Total Debt to Total Equity 0.03
EBITDA Margin 6.04
Particulars MAR 2022 (Values in Cr)
Book Value / Share 11.56
ROE % 20.27
ROCE % 21.70
Total Debt to Total Equity 0.04
EBITDA Margin 9.50
Particulars MAR 2021 (Values in Cr)
Book Value / Share 8.47
ROE % 25.85
ROCE % 20.94
Total Debt to Total Equity 0.21
EBITDA Margin 10.99
Particulars MAR 2020 (Values in Cr)
Book Value / Share 6.32
ROE % 10.24
ROCE % 8.48
Total Debt to Total Equity 0.49
EBITDA Margin 9.14
Particulars MAR 2024 (Values in Cr)
Book Value / Share 17.39
ROE % 13.29
ROCE % 17.08
Total Debt to Total Equity 0.03
EBITDA Margin 11.34
Particulars MAR 2023 (Values in Cr)
Book Value / Share 15.26
ROE % 6.71
ROCE % 8.78
Total Debt to Total Equity 0.03
EBITDA Margin 6.20
Particulars MAR 2022 (Values in Cr)
Book Value / Share 11.97
ROE % 19.38
ROCE % 20.85
Total Debt to Total Equity 0.03
EBITDA Margin 9.62
Particulars MAR 2021 (Values in Cr)
Book Value / Share 8.92
ROE % 24.43
ROCE % 19.57
Total Debt to Total Equity 0.21
EBITDA Margin 11.16
Particulars MAR 2020 (Values in Cr)
Book Value / Share 6.83
ROE % 9.86
ROCE % 8.04
Total Debt to Total Equity 0.48
EBITDA Margin 9.33
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 52.11
Total Assets 1293.20
Total Liabilities 1293.20
Total Equity 847.22
Share Outstanding 511168708
Price to Book Ratio 2.42
Return on Assets (%) 7.43
Return on Capital (%) 10.97
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 56.30
Total Assets 1110.49
Total Liabilities 1110.49
Total Equity 752.44
Share Outstanding 511168708
Price to Book Ratio 1.68
Return on Assets (%) 3.48
Return on Capital (%) 4.97
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 45.97
Total Assets 1070.05
Total Liabilities 1070.05
Total Equity 578.10
Share Outstanding 477826203
Price to Book Ratio 3.06
Return on Assets (%) 9.50
Return on Capital (%) 17.04
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 67.89
Total Assets 858.14
Total Liabilities 858.14
Total Equity 424.29
Share Outstanding 449826203
Price to Book Ratio 3.60
Return on Assets (%) 11.31
Return on Capital (%) 22
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 38.88
Total Assets 663.46
Total Liabilities 663.46
Total Equity 283.59
Share Outstanding 449793203
Price to Book Ratio 1.40
Return on Assets (%) 5.06
Return on Capital (%) 11.35
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 50.47
Total Assets 1279.30
Total Liabilities 1279.30
Total Equity 889.02
Share Outstanding 511168708
Price to Book Ratio 2.42
Return on Assets (%) 8.67
Return on Capital (%) 12.09
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 55.90
Total Assets 1105.54
Total Liabilities 1105.54
Total Equity 780.11
Share Outstanding 511168708
Price to Book Ratio 1.68
Return on Assets (%) 4.18
Return on Capital (%) 5.74
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 45.54
Total Assets 1033.26
Total Liabilities 1033.26
Total Equity 598.16
Share Outstanding 477826203
Price to Book Ratio 3.06
Return on Assets (%) 9.78
Return on Capital (%) 16.39
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 66.98
Total Assets 847.49
Total Liabilities 847.49
Total Equity 444.97
Share Outstanding 449793203
Price to Book Ratio 3.60
Return on Assets (%) 11.12
Return on Capital (%) 20.4
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 38.03
Total Assets 661.98
Total Liabilities 661.98
Total Equity 307.24
Share Outstanding 449793203
Price to Book Ratio 1.40
Return on Assets (%) 4.88
Return on Capital (%) 10.12
Particulars MAR 2024 (Values in Cr)
Net Income 135.41
Cash from Operations 111.48
Cash from Investing -83.30
Cash from Financing 5.20
Net change in Cash -4.72
Free Cash Flow 182.87
Particulars MAR 2023 (Values in Cr)
Net Income 55.75
Cash from Operations -74.61
Cash from Investing -46.50
Cash from Financing 143.54
Net change in Cash 5.86
Free Cash Flow -38.99
Particulars MAR 2022 (Values in Cr)
Net Income 126.70
Cash from Operations -35.30
Cash from Investing -31.67
Cash from Financing 66.33
Net change in Cash -25.58
Free Cash Flow 10.13
Particulars MAR 2021 (Values in Cr)
Net Income 98.51
Cash from Operations 52.28
Cash from Investing -70.35
Cash from Financing 47.27
Net change in Cash 27.74
Free Cash Flow 74.08
Particulars MAR 2020 (Values in Cr)
Net Income 39.10
Cash from Operations 16.89
Cash from Investing -12.46
Cash from Financing 5.48
Net change in Cash 4.04
Free Cash Flow 33.55
Particulars MAR 2024 (Values in Cr)
Net Income 148.97
Cash from Operations 114.72
Cash from Investing -83.60
Cash from Financing 0.28
Net change in Cash -5.95
Free Cash Flow 185.95
Particulars MAR 2023 (Values in Cr)
Net Income 63.04
Cash from Operations -85.84
Cash from Investing -36.19
Cash from Financing 144.19
Net change in Cash 5.88
Free Cash Flow -50.29
Particulars MAR 2022 (Values in Cr)
Net Income 125.54
Cash from Operations -44.47
Cash from Investing -22.64
Cash from Financing 66.41
Net change in Cash -25.09
Free Cash Flow 0.68
Particulars MAR 2021 (Values in Cr)
Net Income 94.24
Cash from Operations 49.31
Cash from Investing -69.08
Cash from Financing 47.46
Net change in Cash 27.68
Free Cash Flow 71.05
Particulars MAR 2020 (Values in Cr)
Net Income 37.48
Cash from Operations 16.37
Cash from Investing -12.07
Cash from Financing 4.64
Net change in Cash 3.43
Free Cash Flow 33.02
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High

MOREPEN LAB. LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
60.17 -3.92 redarrow
red-green-graph indicator
3 Bearish
13 Bullish
  • 5 Days 60.10
  • 26 Days 54.30
  • 10 Days 57.90
  • 50 Days 54.70
  • 12 Days 57.20
  • 100 Days 59.20
  • 20 Days 55.10
  • 200 Days 61.50
62.46 PIVOT

First Support

61.55

First Resistance

63.54

Second Support

60.47

Second Resistance

64.45

Third Support

59.56

Third Resistance

65.53

RSI

61.84

ADX

21.40

MACD

2.84

Williams % R

-27.00

Commodity Channel Index (CCI)

124.36

Date

2025-04-30

Week

3223346.00

Same Day

1729670.00

Month

2134011.00

1 Year

1.59

3 Year

1.15

Over 1 Month

21.85%

down

Over 1 Year

20.21%

down

Over 3 Months

-3.63%

down

Over 3 Years

8.27%

down

Over 6 Months

-23.75%

down

Over 5 Years

26.87%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

MOREPEN LAB. LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
60.73%
Promoter Holdings
35.65%
FII
1.93%
DII
1.67%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Pinfold Overseas Limited 3.853E7 (7.03%) Public Shareholding
Scope Credits And Financial Services Pvt. Ltd. 1.5575405E7 (2.84%) Shareholding of Promoter and Promoter Group
Concept Credits And Consultants Pvt. Ltd. 1.5347724E7 (2.8%) Shareholding of Promoter and Promoter Group
Brook Investments And Financial Services Pvt. Ltd 1.5159252E7 (2.77%) Shareholding of Promoter and Promoter Group
Solitary Investments And Financial Services Pvt. Ltd. 1.5114045E7 (2.76%) Shareholding of Promoter and Promoter Group
Solace Investments And Financial Services Pvt. Ltd. 1.508279E7 (2.75%) Shareholding of Promoter and Promoter Group
React Investments And Financial Services Pvt. Ltd. 1.4942134E7 (2.73%) Shareholding of Promoter and Promoter Group
Mid Med Financial Services And Investments Pvt. Ltd. 1.4973813E7 (2.73%) Shareholding of Promoter and Promoter Group
Epitome Holdings Pvt.ltd. 1.450082E7 (2.65%) Shareholding of Promoter and Promoter Group
Seed Securities And Services Pvt. Ltd. 1.432878E7 (2.61%) Shareholding of Promoter and Promoter Group
Square Investments And Financial Services Pvt. Ltd. 1.4102075E7 (2.57%) Shareholding of Promoter and Promoter Group
Morepen Laboratories Limited 5572152.0 (1.02%) Public Shareholding
Sushil Suri 5501510.0 (1.0%) Shareholding of Promoter and Promoter Group
Anju Suri 5186369.0 (0.95%) Shareholding of Promoter and Promoter Group
Liquid Holdings Pvt. Ltd. 5003000.0 (0.91%) Shareholding of Promoter and Promoter Group
Sonia Pankaj Bajaj 3679718.0 (0.67%) Shareholding of Promoter and Promoter Group
Sanjay Suri 3417240.0 (0.62%) Shareholding of Promoter and Promoter Group
Sunita Suri 3192240.0 (0.58%) Shareholding of Promoter and Promoter Group
Varun Suri 3052357.0 (0.56%) Shareholding of Promoter and Promoter Group
Mamta Suri 3004000.0 (0.55%) Shareholding of Promoter and Promoter Group
Sanjay Suri (sanjay Suri Sons Huf) 2100000.0 (0.38%) Shareholding of Promoter and Promoter Group
Shalu Suri 2052250.0 (0.37%) Shareholding of Promoter and Promoter Group
Anubhav Suri (arun Suri Sons Huf) 1500000.0 (0.27%) Shareholding of Promoter and Promoter Group
Sushil Suri (sushil Suri Sons Huf) 1201560.0 (0.22%) Shareholding of Promoter and Promoter Group
Gulfy Malhotra 1150000.0 (0.21%) Shareholding of Promoter and Promoter Group
Kanak Suri 997060.0 (0.18%) Shareholding of Promoter and Promoter Group
Rajas Suri (kb Suri Sons Huf) 972830.0 (0.18%) Shareholding of Promoter and Promoter Group
Anubhav Suri 782134.0 (0.14%) Shareholding of Promoter and Promoter Group
Aanandi Suri 750000.0 (0.14%) Shareholding of Promoter and Promoter Group
Master Arjun Suri 697060.0 (0.13%) Shareholding of Promoter and Promoter Group
Aanchal Suri 685922.0 (0.13%) Shareholding of Promoter and Promoter Group
Sara Suri 705000.0 (0.13%) Shareholding of Promoter and Promoter Group
Late P.l. Suri 400000.0 (0.07%) Shareholding of Promoter and Promoter Group
Rajas Suri 155000.0 (0.03%) Shareholding of Promoter and Promoter Group
Aakriti Suri 55000.0 (0.01%) Shareholding of Promoter and Promoter Group
Late Kanta Suri 1510.0 (0.0%) Shareholding of Promoter and Promoter Group
Praduman Lal Suri Huf 2990.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

MOREPEN LAB. LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
07 Nov 2000 10.0 2.0 22 Nov 2000
06 Nov 2000 10.0 2.0 22 Nov 2000
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
07 Nov 2000 10.0 2.0 22 Nov 2000
06 Nov 2000 10.0 2.0 22 Nov 2000

Morepen Lab share result highlights

In the second quarter of fiscal year 2024-25, Morepen Laboratories Limited reported a consolidated net profit of ₹21.26 crore, marking a 45% increase from ₹14.63 crore in the previous quarter. Revenue from operations rose by 5.2% quarter-on-quarter to ₹421.77 crore. The company's EBITDA margin improved to 12.25%, reflecting enhanced operational efficiency. These robust financial results have positively influenced the Morepen Lab share price, reflecting increased investor confidence.

Morepen Lab share annual reports

The 2023-24 annual report of Morepen Laboratories Limited provides comprehensive insights into its financial performance and strategic initiatives. The company achieved a total income of ₹1,744.6 crore, registering a growth of 7.7% from the previous year. The report highlights Morepen's focus on expanding its product portfolio, enhancing operational efficiency, and implementing cost optimisation measures. These efforts have contributed to a stable Morepen Laboratories share price by showcasing the company's commitment to growth and profitability.

Morepen Lab share dividend

For the fiscal year 2023-24, Morepen Laboratories Limited declared a total dividend of ₹1.50 per share, reflecting its commitment to returning value to shareholders. This consistent dividend payout, supported by strong financial performance, has positively impacted the Morepen Lab share price by enhancing investor confidence.

Popular FAQs

1. Who is the CEO of Morepen Lab Ltd?

As of November 2024, the Chairman and Managing Director of Morepen Laboratories Limited is Mr. Sushil Suri. He oversees the company's operations and strategic initiatives, influencing the Morepen Lab share price through effective leadership and business expansion.

 

2. When was Morepen Lab Ltd established?

Morepen Laboratories Limited was established in 1984. Over the decades, it has grown into one of India's leading pharmaceutical companies, impacting the Morepen Laboratories share price through its extensive operations and market presence.

 

3. What factors influence Morepen Lab Ltd share price fluctuations?

The Morepen Lab share price is influenced by various factors, including the company's financial performance, product launches, regulatory developments, and broader economic conditions. Additionally, market demand for pharmaceutical products, competition, and research and development outcomes play significant roles in determining share price movements.

 

4. Is Morepen Lab debt free?

No, Morepen Laboratories Limited is not entirely debt-free. The company utilises debt financing to fund its capital-intensive projects and expansion plans. However, it maintains a balanced debt-to-equity ratio, ensuring financial stability and the ability to meet its obligations without adversely affecting the Morepen Laboratories share price.

 

5. What is the CAGR of Morepen Lab share?

Over the past five years, the Compound Annual Growth Rate (CAGR) of Morepen Lab shares has been approximately 15%. This indicates a steady growth in the Morepen Lab share price, reflecting the company's consistent financial performance and strategic initiatives.

 

6. How has the Morepen Lab share price performed over the past year?

Over the past year, the Morepen Lab share price has experienced fluctuations influenced by market conditions and company performance. As of November 2024, the share price has shown a modest increase compared to the same period last year, reflecting investor confidence in the company's strategic direction and financial health.

 

MOREPEN LAB. LTD Share Price

Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L.

The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India. The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally. The company has developed a hi-tech Pharma complex at Morepen Village, Baddi (HP) on 60 acres of land that has various multipurpose pharma facilities for API & finished dosages and a Research Centre.

The company was established in the year 1984. The company has filed 14 patents including 6 international PCT applications. The company has filed an international patent on a new amorphous form of the cholesterol-reducing drug Lipitor (Atorvastatin) that is the largest selling drug in the world. During the year 1991-1992, the company set up the new facilities for bulk manufacture of Cephalexin, 7 ADCA and CIMC Chloride at its existing location. During the year 1992-1993, the company started implementing its expansion plans for manufacture Cephalexin, 7ADCA, CIMC Chloride, Research and Development Block and Formulation unit. The company introduced two latest molecules, Ketrolac Tromethamine and Omeprazole. Also, the company also launched Loratadine and Cisapride.

During the year 1993-1994, the company increased the installed capacity of Bulk Drugs from 162 MT to 245 MT. The company started the commercial production of Ketorolac Tromethamine, which is a potent analgesic. During the year 1994-1995, the company increased the installed capacity of Drugs & Drug Intermediates from 305 MT to 469 MT.

During the year 1995-1996, the company successfully launched high value and high technology products namely, Cisapride & Loratadine. Also, the company launched herbal product namely Paclitaxel, an anti cancer drug. During the year 1996-1997, the company commissioned its own formulation unit, which gave a competitive edge to the company in terms of quality and cost efficiency.

During the year 2000-2001, the company increased the installed capacity of Drugs & Drug Intermediates from 916 MT to 1170 MT. The company signed a joint venture with DiaMed AG of Switzerland, a proven international leader in blood group serology diagnostic products. Also, the company developed and launched wide range of contemporary, lifestyle oriented FMHG (Fast Moving Health Goods) Self Medication products.

During the year 2001-2002, the company increased the installed capacity of Drugs & Drug Intermediates from 1170 MT to 1251 MT. Also, the company further increased installed capacity of Tablets / Capsules from 25080 Nos to 35000 Nos. During the year 2004-2005, the company developed the new polymorphic from V1 and field patent in 33 countries and in the same year, the company started finalizing marketing partner for filing ANDA's for the molecule.

During the year 2005-2006, the company made 52 DMF filing across ten European countries for six products. Also, the company broadened its offering by introduced new product like Ducal, Rythmix, Montelast, Alcoflam, Levopen, Moezole, and Cefpen-S.

During the year 2006-2007, the company improved its presence in the key market of South East Asia, Africa & Australia. During the year, the company acquired more than fifty new prospective customers in Korea, Japan, and Taiwan. During the year, the company started of OTC formulation under the umberalla brand 'Dr. Morepen'.

During the year 2007-2008, the company made the tie ups with several new business segments. Marketing alliance with World leaders like lmmucor, USA (for immuunohematology system & consumables), Teco Medical Instruments, Germany (for coagulation system & consumables), InTec INC. (for ELISA Kits), Access Bio, USA (for Rapid Malaria Kits), helped the diagnostics division to make deeper inroads into both the consumer market and the blood bank and laboratory segment.

In 2010, it launched Cardia Division for Diabetic and Cardiac products. In 2015, it started personal Grooming Division with brand GUBB USA. In 2019, it launched APIs for many anti-diabetic molecules. The Company launched 'IntebactImun' in boosting immunity of adults and kids in 2023. It started manufacturing two more products viz., Blood Pressure Monitors and Pregnancy Testing Kits in 2023.

Parent organization Morepen
NSE symbol MOREPENLAB
Founded 1984
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Morepen Laboratories Ltd?

Answer Field

The share price of Morepen Laboratories Ltd for NSE is ₹ 60.17 and for BSE is ₹ 60.

What is the Market Cap of Morepen Laboratories Ltd?

Answer Field

The market cap of Morepen Laboratories Ltd for NSE is ₹ 30,75.70 Cr. and for BSE is ₹ 30,67.01 Cr. as of now.

What is the 52 Week High and Low of Morepen Laboratories Ltd?

Answer Field

The 52 Week High and Low of Morepen Laboratories Ltd for NSE is ₹ 100.90 and ₹ 42.00 and for BSE is ₹ 100.80 and ₹ 41.66.

How to Buy Morepen Laboratories Ltd share?

Answer Field

You can trade in Morepen Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Morepen Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been 20.21%.

What is the Current Share Price of Morepen Laboratories Ltd?

Answer Field

Morepen Laboratories Ltd share price is for NSE ₹ 60.17 & for BSE ₹ 60 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Morepen Laboratories Ltd Share?

Answer Field

The market cap of Morepen Laboratories Ltd for NSE ₹ 30,75.70 & for BSE ₹ 30,67.01 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Morepen Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Morepen Laboratories Ltd share is 25.45.

What is the PB ratio of Morepen Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Morepen Laboratories Ltd share is 20.95.

How to Buy Morepen Laboratories Ltd Share?

Answer Field

You can trade in Morepen Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Morepen Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Morepen Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Morepen Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|